JPWO2019237053A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019237053A5 JPWO2019237053A5 JP2021518056A JP2021518056A JPWO2019237053A5 JP WO2019237053 A5 JPWO2019237053 A5 JP WO2019237053A5 JP 2021518056 A JP2021518056 A JP 2021518056A JP 2021518056 A JP2021518056 A JP 2021518056A JP WO2019237053 A5 JPWO2019237053 A5 JP WO2019237053A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- mkh2
- drug
- anticoagulant therapy
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- RAKQPZMEYJZGPI-LJWNYQGCSA-N menaquinone-7 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 RAKQPZMEYJZGPI-LJWNYQGCSA-N 0.000 claims description 60
- 235000009464 menaquinone-7 Nutrition 0.000 claims description 60
- 239000011700 menaquinone-7 Substances 0.000 claims description 60
- 239000003146 anticoagulant agent Substances 0.000 claims description 23
- 238000002560 therapeutic procedure Methods 0.000 claims description 23
- 230000002308 calcification Effects 0.000 claims description 21
- 210000001519 tissues Anatomy 0.000 claims description 20
- 230000002429 anti-coagulation Effects 0.000 claims description 18
- VFGNPJRRTKMYKN-LJWNYQGCSA-N menaquinol-7 Chemical compound C1=CC=CC2=C(O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(O)=C21 VFGNPJRRTKMYKN-LJWNYQGCSA-N 0.000 claims description 17
- 230000000694 effects Effects 0.000 claims description 16
- 206010012601 Diabetes mellitus Diseases 0.000 claims description 14
- 201000000522 chronic kidney disease Diseases 0.000 claims description 13
- 230000036823 Plasma Levels Effects 0.000 claims description 11
- 239000003112 inhibitor Substances 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 108010029144 Factor IIa Proteins 0.000 claims description 8
- 108010074860 Factor Xa Proteins 0.000 claims description 8
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 8
- 102000012005 alpha-2-HS-Glycoprotein Human genes 0.000 claims description 8
- 108010075843 alpha-2-HS-Glycoprotein Proteins 0.000 claims description 8
- 238000001631 haemodialysis Methods 0.000 claims description 8
- 230000000322 hemodialysis Effects 0.000 claims description 8
- PJVWKTKQMONHTI-UHFFFAOYSA-N 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 claims description 7
- KXNPVXPOPUZYGB-XYVMCAHJSA-N Argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 claims description 7
- 102000008108 Osteoprotegerin Human genes 0.000 claims description 7
- 108010035042 Osteoprotegerin Proteins 0.000 claims description 7
- 229960005080 Warfarin Drugs 0.000 claims description 7
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 claims description 6
- XHOLNRLADUSQLD-UHFFFAOYSA-N Betrixaban Chemical compound C=1C=C(Cl)C=NC=1NC(=O)C1=CC(OC)=CC=C1NC(=O)C1=CC=C(C(=N)N(C)C)C=C1 XHOLNRLADUSQLD-UHFFFAOYSA-N 0.000 claims description 6
- 229950011103 Betrixaban Drugs 0.000 claims description 6
- 229960003850 Dabigatran Drugs 0.000 claims description 6
- HGVDHZBSSITLCT-JLJPHGGASA-N Edoxaban Chemical compound N([C@H]1CC[C@@H](C[C@H]1NC(=O)C=1SC=2CN(C)CCC=2N=1)C(=O)N(C)C)C(=O)C(=O)NC1=CC=C(Cl)C=N1 HGVDHZBSSITLCT-JLJPHGGASA-N 0.000 claims description 6
- 208000001280 Prediabetic State Diseases 0.000 claims description 6
- KGFYHTZWPPHNLQ-AWEZNQCLSA-N Rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 claims description 6
- 229960003886 apixaban Drugs 0.000 claims description 6
- 229960003856 argatroban Drugs 0.000 claims description 6
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical group N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 claims description 6
- 229960000622 edoxaban Drugs 0.000 claims description 6
- KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 claims description 6
- 229960001318 fondaparinux Drugs 0.000 claims description 6
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 6
- 229960001148 rivaroxaban Drugs 0.000 claims description 6
- 208000009863 Chronic Kidney Failure Diseases 0.000 claims description 5
- 206010038444 Renal failure chronic Diseases 0.000 claims description 4
- 201000000523 end stage renal failure Diseases 0.000 claims description 4
- PFGVNLZDWRZPJW-OPAMFIHVSA-N Otamixaban Chemical compound C([C@@H](C(=O)OC)[C@@H](C)NC(=O)C=1C=CC(=CC=1)C=1C=C[N+]([O-])=CC=1)C1=CC=CC(C(N)=N)=C1 PFGVNLZDWRZPJW-OPAMFIHVSA-N 0.000 claims description 2
- 229950009478 Otamixaban Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 19
- 229940079593 drugs Drugs 0.000 claims 16
- 239000008177 pharmaceutical agent Substances 0.000 claims 2
- QQBKAVAGLMGMHI-WIYYLYMNSA-N (2R,4R)-1-N-(4-chlorophenyl)-2-N-[2-fluoro-4-(2-oxopyridin-1-yl)phenyl]-4-methoxypyrrolidine-1,2-dicarboxamide Chemical compound N1([C@H](C[C@H](C1)OC)C(=O)NC=1C(=CC(=CC=1)N1C(C=CC=C1)=O)F)C(=O)NC1=CC=C(Cl)C=C1 QQBKAVAGLMGMHI-WIYYLYMNSA-N 0.000 claims 1
- 229950007830 eribaxaban Drugs 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- -1 retaxaban Chemical compound 0.000 claims 1
- 102000025380 C-Reactive Protein Human genes 0.000 description 4
- 108010074051 C-Reactive Protein Proteins 0.000 description 4
- 239000003154 D dimer Substances 0.000 description 4
- 108091005597 Vitamin K-dependent proteins Proteins 0.000 description 4
- 239000007894 caplet Substances 0.000 description 4
- 108010052295 fibrin fragment D Proteins 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- 210000002381 Plasma Anatomy 0.000 description 3
- 210000002966 Serum Anatomy 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- FJLGEFLZQAZZCD-JUFISIKESA-N (3S,5R)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-JUFISIKESA-N 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N Lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- 102000016216 Matrix Gla protein Human genes 0.000 description 2
- 102000004067 Osteocalcin Human genes 0.000 description 2
- 108090000573 Osteocalcin Proteins 0.000 description 2
- 206010034636 Peripheral vascular disease Diseases 0.000 description 2
- VGYFMXBACGZSIL-MCBHFWOFSA-N Pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 2
- 229960002965 Pravastatin Drugs 0.000 description 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N Pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 2
- 102000017975 Protein C Human genes 0.000 description 2
- 229960000856 Protein C Drugs 0.000 description 2
- 102000029610 Protein S Human genes 0.000 description 2
- 108010066124 Protein S Proteins 0.000 description 2
- 229940096437 Protein S Drugs 0.000 description 2
- BPRHUIZQVSMCRT-VEUZHWNKSA-N Rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N Simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- 229940046010 Vitamin K Drugs 0.000 description 2
- 229930003448 Vitamin K Natural products 0.000 description 2
- 229940019697 Vitamin K containing hemostatics Drugs 0.000 description 2
- 108010063628 acarboxyprothrombin Proteins 0.000 description 2
- 229960005370 atorvastatin Drugs 0.000 description 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229960003765 fluvastatin Drugs 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- 108010057546 matrix Gla protein Proteins 0.000 description 2
- 108060005018 mobB Proteins 0.000 description 2
- 229960002797 pitavastatin Drugs 0.000 description 2
- 229960000672 rosuvastatin Drugs 0.000 description 2
- 229960002855 simvastatin Drugs 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 230000001340 slower Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 235000019168 vitamin K Nutrition 0.000 description 2
- 239000011712 vitamin K Substances 0.000 description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 description 2
- 102100015724 CRP Human genes 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- 206010040882 Skin lesion Diseases 0.000 description 1
- 208000005475 Vascular Calcification Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 230000000779 depleting Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000003902 lesions Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 230000003843 mucus production Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024043503A JP2024073612A (ja) | 2018-06-08 | 2024-03-19 | 組織石灰化を予防または治療するための方法および組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862682796P | 2018-06-08 | 2018-06-08 | |
| US62/682,796 | 2018-06-08 | ||
| PCT/US2019/036138 WO2019237053A1 (fr) | 2018-06-08 | 2019-06-07 | Méthodes et compositions destinés à la prévention ou au traitement de la calcification des tissus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024043503A Division JP2024073612A (ja) | 2018-06-08 | 2024-03-19 | 組織石灰化を予防または治療するための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021527128A JP2021527128A (ja) | 2021-10-11 |
| JPWO2019237053A5 true JPWO2019237053A5 (fr) | 2022-06-10 |
Family
ID=68765387
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021518056A Pending JP2021527128A (ja) | 2018-06-08 | 2019-06-07 | 組織石灰化を予防または治療するための方法および組成物 |
| JP2024043503A Pending JP2024073612A (ja) | 2018-06-08 | 2024-03-19 | 組織石灰化を予防または治療するための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024043503A Pending JP2024073612A (ja) | 2018-06-08 | 2024-03-19 | 組織石灰化を予防または治療するための方法および組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (7) | US10688064B2 (fr) |
| EP (1) | EP3801477A4 (fr) |
| JP (2) | JP2021527128A (fr) |
| KR (1) | KR20210018423A (fr) |
| CN (1) | CN113038940A (fr) |
| AU (1) | AU2019282420A1 (fr) |
| CA (1) | CA3102977A1 (fr) |
| IL (1) | IL279245B2 (fr) |
| MX (1) | MX2020013302A (fr) |
| SG (1) | SG11202012070YA (fr) |
| WO (1) | WO2019237053A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019282420A1 (en) | 2018-06-08 | 2021-01-07 | Epizon Pharma, Inc. | Methods and compositions for preventing or treating tissue calcification |
| JP2021527129A (ja) | 2018-06-08 | 2021-10-11 | エピゾン・ファーマ・インコーポレイテッドＥｐｉｚｏｎ Ｐｈａｒｍａ， Ｉｎｃ． | カルシフィラキシスを予防または治療するための方法および組成物 |
| CA3111108A1 (fr) | 2018-09-12 | 2020-03-19 | Epizon Pharma, Inc. | Compositions de menaquinol et procedes de traitement |
| EP3938040A2 (fr) * | 2019-03-12 | 2022-01-19 | Kaydence Pharma AS | Utilisation de vitamine k en combinaison avec des anticoagulants |
| CN117836317A (zh) * | 2021-07-05 | 2024-04-05 | 马斯特里赫特大学 | 治疗钙晶体沉积疾病的手段和方法 |
| WO2023129413A1 (fr) * | 2021-12-31 | 2023-07-06 | Ingredient Fusion, Llc | Procédé de complexation moléculaire, formulation et fabrication pour un meilleur apport en nutriments |
| WO2024071848A1 (fr) * | 2022-09-27 | 2024-04-04 | 경북대학교 산학협력단 | Procédé de dépistage d'un agent thérapeutique pour la calcification vasculaire |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050176778A1 (en) * | 2001-08-03 | 2005-08-11 | Vitak Bv | Isoprenyl derivatives and their use in the title treatment and prevention of osteoporosis and cardiovascular calcification |
| WO2005030190A1 (fr) * | 2003-09-26 | 2005-04-07 | Natural Asa | Compositions de menaquinone 7 naturelle |
| PL1728507T3 (pl) | 2005-06-03 | 2011-09-30 | Nattopharma Asa | Zastosowanie witaminy K w celu cofnięcia zwapnienia naczyń krwionośnych |
| PL2046312T3 (pl) * | 2006-07-14 | 2021-02-08 | Kaydence Pharma As | Produkty farmaceutyczne i nutraceutyki zawierające witaminę K2 |
| GB0817528D0 (en) | 2008-09-24 | 2008-10-29 | Syntavit As | Process |
| US20130237610A1 (en) * | 2010-11-01 | 2013-09-12 | Dilip Mehta | Dynamic balancing of autonomic nervous system through vitamin mk-7 |
| GB201203705D0 (en) | 2012-03-02 | 2012-04-18 | Kappa Bioscience As | Prodrugs |
| US10159787B2 (en) | 2012-06-18 | 2018-12-25 | Fresenius Kabi Deutschland Gmbh | Port cannula system for puncturing port catheters |
| WO2014191466A1 (fr) * | 2013-05-28 | 2014-12-04 | Nattopharma Asa | Apport complémentaire de ménaquinone et santé vasculaire |
| GB201314245D0 (en) | 2013-08-08 | 2013-09-25 | Kappa Bioscience As | Provitamins |
| US20180199610A1 (en) | 2015-02-20 | 2018-07-19 | Vitak B.V. | Vitamin k and capillary function |
| CN107428645A (zh) | 2015-03-20 | 2017-12-01 | 诺西斯有限公司 | 固体形式的还原甲萘醌 |
| IT201700085412A1 (it) | 2017-07-26 | 2019-01-26 | Pharmanutra S P A | Composizione per uso nella prevenzione e nel trattamento di patologie dell'apparato cardiovascolare |
| US10368858B1 (en) | 2018-01-25 | 2019-08-06 | Ring Orthopedics, Inc. | Suture passer |
| JP2021527129A (ja) | 2018-06-08 | 2021-10-11 | エピゾン・ファーマ・インコーポレイテッドＥｐｉｚｏｎ Ｐｈａｒｍａ， Ｉｎｃ． | カルシフィラキシスを予防または治療するための方法および組成物 |
| AU2019282420A1 (en) | 2018-06-08 | 2021-01-07 | Epizon Pharma, Inc. | Methods and compositions for preventing or treating tissue calcification |
-
2019
- 2019-06-07 AU AU2019282420A patent/AU2019282420A1/en active Pending
- 2019-06-07 EP EP19814212.7A patent/EP3801477A4/fr active Pending
- 2019-06-07 CN CN201980052695.9A patent/CN113038940A/zh active Pending
- 2019-06-07 KR KR1020217000120A patent/KR20210018423A/ko unknown
- 2019-06-07 CA CA3102977A patent/CA3102977A1/fr active Pending
- 2019-06-07 WO PCT/US2019/036138 patent/WO2019237053A1/fr unknown
- 2019-06-07 SG SG11202012070YA patent/SG11202012070YA/en unknown
- 2019-06-07 MX MX2020013302A patent/MX2020013302A/es unknown
- 2019-06-07 US US16/435,241 patent/US10688064B2/en active Active
- 2019-06-07 JP JP2021518056A patent/JP2021527128A/ja active Pending
- 2019-06-07 IL IL279245A patent/IL279245B2/en unknown
-
2020
- 2020-03-12 US US16/817,374 patent/US10744102B2/en active Active
- 2020-03-12 US US16/817,363 patent/US10744101B2/en active Active
- 2020-03-12 US US16/817,347 patent/US10874623B2/en active Active
- 2020-11-20 US US17/100,256 patent/US11033515B2/en active Active
-
2021
- 2021-05-11 US US17/317,488 patent/US11723882B2/en active Active
-
2023
- 2023-06-29 US US18/215,989 patent/US20240009144A1/en active Pending
-
2024
- 2024-03-19 JP JP2024043503A patent/JP2024073612A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3275438B1 (fr) | Procédés de prévention des événements cardio-vasculaires chez des populations dyslipidémiques à risques résiduels | |
| Kurban et al. | Cutaneous manifestations of chronic kidney disease | |
| Daniel | Lipid management in patients with type 2 diabetes | |
| TWI744215B (zh) | 檸檬酸鐵用於治療及降低慢性腎病患者之與不良心臟事件有關之死亡率及發病率之用途 | |
| Toida et al. | Takotsubo cardiomyopathy after vaccination for coronavirus disease 2019 in a patient on maintenance hemodialysis | |
| KR20170020514A (ko) | 중증 고중성지방혈증의 치료 | |
| JPWO2019237053A5 (fr) | ||
| Azzeh et al. | Vitamin C supplementation and serum uric acid: A reaction to hyperuricemia and gout disease | |
| Trailokya | Acenocoumarol in Thromoembolic Disorders | |
| Smith et al. | The new face of hyperlipidemia management: proprotein convertase subtilisin/kexin inhibitors (PCSK-9) and their emergent role as an alternative to statin therapy | |
| TW202310842A (zh) | 高強度他汀弱反應物之治療 | |
| JPWO2019237054A5 (fr) | ||
| Li et al. | Low dose of interferon‑α improves the clinical outcomes of docetaxel in patients with castration‑resistant prostate cancer: A pilot study | |
| Schneider | Improving macrovascular outcomes in type 2 diabetes: outcome studies in cardiovascular risk and metabolic control | |
| Avram et al. | Identifying patient candidates for IL-1 inhibition: lessons from real-world cases | |
| US20200360331A1 (en) | COMPOSITIONS COMPRISING 15-HEPE AND/OR 15-HETrE AND METHODS OF TREATING OR PREVENTING CARDIOMETABOLIC DISEASE, METABOLIC SYNDROME, AND/OR RELATED DISEASES | |
| CN111588719A (zh) | 辛伐他汀在制备治疗新冠肺炎药物中的应用 | |
| WO2014034871A1 (fr) | Médicament pour la prévention ou le traitement de la dyslipidémie | |
| Breijo-Márquez | Misuse of the Drug Acenocoumarol in a Population of 250 Inhabitants with Non-valvular Atrial Fibrillation Assessed in a Region of Southeaster of Spain | |
| EP3442509A1 (fr) | Méthodes pour traiter les évènements indésirables cardiovasculaires, cérébrovasculaires ou rénovasculaires induits par les ains | |
| JP6184960B2 (ja) | メラトニンの新規用途 | |
| Yahya et al. | Old drug with new milestone: chloroquine and hydroxychloroquine in SARS-COV-2 (COVID-19) with multifaceted effects in other diseases | |
| RU2465905C2 (ru) | Способ замедления преждевременного старения у работников газодобывающего предприятия | |
| HUSSAIN et al. | Lipid-Modifying Drugs | |
| JP6443935B2 (ja) | 動脈硬化の治療または予防のためのアスピリンおよび葉酸の併用 |